dynaCERT inc. Reaches Major Milestone in Third Party

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
dynaCERT inc. Reaches Major Milestone in Third Party Validation

TORONTO, ON --(Marketwired - November 15, 2016) - dyna CERT Inc. ( TSX VENTURE : DYA ) ( OTC : DYFSF ) (" dyna CERT" or the "Company") is pleased to announce that a major milestone has been reached in the development and validation of their HydraGen™ unit for Class 8 truck application. Fuel consumption and emissions testing of the HydraGen™ unit on a Class 8 truck while exposed to real world road load and environmental conditions was carried out using the Climatic Wind Tunnel (CWT) of the Automotive Centre of Excellence (ACE) at the University of Ontario Institute of Technology (UOIT) in Oshawa, Ontario.

The objective of this dynamometer testing was to simulate real-life environments with high accuracy and repeatable conditions on an in-service Class 8 truck to determine how much H 2 /O 2 was required for a minimum of 8% fuel reduction while at the same time maintaining the same power and torque.

Fuel consumption was measured by rerouting the fuel supply system to an external fuel drum placed on a precision scale. As fuel was consumed the scale measured the weight of the drum over the time of the test. The fuel weight and time were recorded by the CWT data acquisition system. Emissions were measured by using portable emissions equipment supplied by dyna CERT.

Several trials were done with two different Class 8 tractors at different combinations of velocity, force load and H 2 /O 2 settings.

There was 20+ hours of testing completed producing over 550 pages of valuable data which has been instrumental in the further development and algorithms for our new Smart ECU.

While altering flow of gases, and depending on different settings of H 2 /O 2 , test results verified a range of fuel consumption reductions from 2.7% to 19.2% equally on post EGR and pre-EGR engines.

Emission reduction ranged from 10% to 40% of greenhouse gases (Carbon Monoxide, Carbon Dioxide, Nitrogen Oxide) and greater than 65% reduction in particulate matter.

About ACE

ACE is a research and testing facility that offers chambers and technology for climatic, structural durability and life-cycle testing and research. Facilities include one of the largest and most sophisticated climatic wind tunnels on the planet. In this test chamber, wind speeds can reach 280 kph with temperatures that range from -40 to +60°C. With our solar arrays and storm generators we can create any weather condition imaginable from sweltering jungle downpours to the paralyzing cold of an arctic storm. We use these chambers to test automotive and aerospace products, to improve the performance of elite athletes and to provide services to many other markets including the Unmanned Aerial Vehicle industry. More information can be found at ace.uoit.ca .

Jim Payne, President & CEO of dyna CERT states, "We are pleased to announce these positive results. The management and engineering team at ACE was a pleasure to work with. Their professionalism and commitment to work through 20+ straight hours of testing was very impressive. As a Canadian company, we look forward to an ongoing relationship working with this state of the art Canadian facility, the "Automotive Centre of Excellence", as we further develop our product suite and offering to the market."

About dyna CERT Inc.

dyna CERT Inc. manufactures, distributes, and installs Carbon Emission Reduction Technology for use with internal combustion engines. Our patent-pending technology creates hydrogen and oxygen on-demand through electrolysis and supplies these additives through the air intake to enhance combustion, resulting in lower carbon emissions and greater fuel efficiency. Our technology is currently in use with on-road applications. More information can be found at www. dyna CERT.com .

READER ADVISORY

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to periodic updates of results, testing programs and results, negotiations with third parties concerning potential business transactions, and the timing of certain going forward projects. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

On Behalf of the Board

Murray James Payne, CEO

For more information, please contact: Jim Payne, CEO & President dyna CERT Inc. #101 - 501 Alliance Avenue Toronto, Ontario M6N 2J1 (416) 766-9691 x 2 jpayne@dynaCERT.com Investor Relations dyna CERT Inc. Nancy Massicotte (416) 766-9691 x 1 ir@dynaCERT.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading